David Schiff headshot

David Schiff

Unit: School of Medicine
Department: Department of Neurology
Office location and address
1415 Jefferson Park Ave
Charlottesville, Virginia 22903
A.B., General Studies, Harvard University, Cambridge, MA
M.D., Medicine, Harvard Medicine School, Boston, MA
Intern, Internal Medicine, Brigham & Women’s Hospital, Harvard Medical School
Resident, Neurology, Harvard Longwood Neurology, Boston, MA
Fellowship, Neuro-oncology, Memorial Sloan Kettering Cancer Center, New York, NY
Fellowship, Neuro-oncology, Mayo Clinic, Rochester, MN

Dr. Schiff is the Harrison Distinguished Professor of Neurology, Neurological Surgery and Medicine. He is the co-director of the UVA Neuro-Oncology Center. His specialties include clinical trials for malignant brain tumors and the management of neurological complications of cancer and its therapies. He has led or co-led numerous NCI-funded brain tumor and pharmaceutical clinical trials.

Dr. Schiff serves on the NCI brain malignancy steering committee and chairs the ECOG-ACRIN brain tumor working group. He also serves on several editorial boards, most notably as the associate editor of the journal, Neuro-Oncology.

Phase I/II Study of BGB-290 with Temozolomide in Recurrent Gliomas with IDH1/2 Mutations
Source: Johns Hopkins University, The
November 08, 2020 – November 07, 2023
Source: Global Coalition For Adaptive Research Inc.
June 16, 2020 – June 15, 2023
A Phase 1b Trial of CB-839 in Combination with Radiation Therapy and Temozolomide in Patients with IDH-mutated Diffuse Astrocytoma and Anaplastic Astrocytoma
Source: Johns Hopkins University, The
August 27, 2019 – February 28, 2023
A Phase I/II Study of Nivolumab plus or minus Ipilimumab in Combination with Multi-fraction Stereotactic Radiosurgery for Recurrent High-grade Radiation-relapsed Meningioma
Source: Johns Hopkins University, The
April 29, 2019 – February 28, 2023
A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) that are Causing Significant Morbidity
Source: Springworks Therapeutics Operating Company, Inc.
December 06, 2019 – December 05, 2022
INdividualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT)
Source: Dana-Farber Cancer Institute, Inc.
September 06, 2017 – September 05, 2022
Maintenance Obinutuzumab for Primary Central Nervous System Lymphoma Complete Responders
Source: Oregon Health & Science University
July 16, 2018 – July 15, 2022
MD-NERS A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation
Source: Brigham & Women's Hospital, Inc.
January 21, 2015 – September 06, 2021
MD-NERS Phase II trial of SMO/AKT/NF2 Inhibitors in progressive meningiomas with SMO/AKT/NF2 mutations
Source: Brigham & Women's Hospital, Inc.
September 01, 2015 – August 31, 2021
NCTN High Performance Site Initiative
Source: PPD Development, Inc.
November 01, 2017 – December 31, 2020
MD-NEUR David Schiff Consulting Agreement with Cavion Pharmaceuticals
Source: Cavion, Inc.
August 01, 2016 – July 31, 2020
INdividualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT) - control arm
Source: Dana-Farber Cancer Institute, Inc.
January 01, 2017 – January 01, 2020
MD-NERS Angiochem Phase II MultiCenter Study ANG1005 for Recurrent High-Grade Glioma-Schiff
Source: AngioChem Inc.
March 12, 2014 – March 12, 2018
MD-NERS Phase I Trial of Pomalidomide for Patients with Relapsed/Refractory Primary CNS Lymphoma and Patients with Newly DIagnosed or Relapsed/Refractory Primary Vitreoretinal Lymphoma
Source: Mayo Clinic Jacksonville
January 23, 2014 – January 23, 2018
MD-NERS A Phase 2 Dose-Escalation Study of TPI 287 in Combination with Bevacizumab in Adults with Recurrent or Progressive Glioblastoma Following a Bevacizumab-Containing Regimen
Source: Cortice Biosciences, Inc.
August 11, 2014 – December 31, 2017
MD-NERS Phase I/Comparative Randomized Phase II Trial of TRC105 plus Bevacizumab versus Bevacizumab in Bevacizumab-Naive Patients with Recurrent Glioblastoma Multiform (N1174)
Source: Brigham & Women's Hospital, Inc.
January 01, 2015 – July 07, 2017
Phase II Trial of Bevacizumab for Recurrent or Progressive Meningioma
Source: Northwestern University
March 22, 2011 – May 01, 2017
MD-NERS Phase I/II study of AMG 386 with and without bevacizumab for recurrent glioblastoma
Source: Dana-Farber Cancer Institute, Inc.
March 20, 2013 – March 20, 2017
Study of the Safety and Efficacy of ICT-107
Source: Aptiv Solutions, Inc.
August 25, 2011 – August 15, 2016
Commonwealth Foundation for Cancer Research
Source: Commonwealth Cancer Foundation for Research
June 01, 2002 – December 31, 2015
A Pilot Phase II Study of OSI-774 & Temozolomide
Source: Mayo Clinic Rochester
January 01, 2005 – December 31, 2014
MD-NERS Phase I/II Study of ZD6474 with Radiation Therapy and Concomitnant Adjuvant Temozolomide for Newly-Diagnosed Glioblastoma
Source: Dana-Farber Cancer Institute, Inc.
December 05, 2007 – December 31, 2014
Phase II Trial of Triple Receptor Tyrosine Kinase Receptor Inhibitor BIBF 1120
Source: Dana-Farber Cancer Institute, Inc.
October 03, 2012 – October 03, 2014
MD-NERS Phase II Study Evaluating the Efficacy & Safety of Onartuzumab (MetMab) in combination with Vevacizumab or Onartuzumab Monotherapy in Patients with Recurrent Glioblastoma
Source: Genentech, Inc
July 23, 2012 – July 23, 2014
MD-NERS Phase I/II Study of LBH589 and Bevacizumab in Patients with Recurrent High Grade Glioma
Source: Dana-Farber Cancer Institute, Inc.
August 07, 2009 – June 30, 2014
MD-NERS A Phase II Study of Sunitinib in Patients with Inoperable or Recurrent Meningiomas
Source: Memorial Sloan-Kettering Cancer Center
August 27, 2008 – June 30, 2014
MD-NERS A Phase 1 Dose Finding Study if the Safety & Pharmacokinetics of XL184 Administered Orally in Combination with Temozolomide and Radiation Therapy in the First line Treatment of Subjects with Glioblastoma: XL184-002
Source: Exelixis, Inc.
August 19, 2009 – March 31, 2014
MD-NERS A Phase II/III Randomized Study of CDX-110 with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme
Source: Celldex Therapeutics, Inc.
October 17, 2007 – November 13, 2013
MD-NERS A Phase 2 Study of XL184 in Subjects with Progressive or Recurrent Glioblastoma Multiforme in first or second Relapse: XL184-201
Source: Exelixis, Inc.
April 29, 2009 – October 29, 2013
  • 2011-2018 Best Doctors in America® List
  • 2015 One of America's Top Cancer Doctors, Newsweek®